PortfoliosLab logo
Roivant Sciences Ltd. (ROIV)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

BMG762791017

CUSIP

612657106

IPO Date

Oct 1, 2021

Highlights

Market Cap

$8.19B

EPS (TTM)

-$1.00

Total Revenue (TTM)

$68.63M

Gross Profit (TTM)

$62.34M

EBITDA (TTM)

-$676.02M

Year Range

$8.73 - $13.06

Target Price

$16.75

Short %

9.63%

Short Ratio

5.86

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Roivant Sciences Ltd. (ROIV) returned -10.06% year-to-date (YTD) and -5.42% over the past 12 months.


ROIV

YTD

-10.06%

1M

7.58%

6M

-10.36%

1Y

-5.42%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

3.72%

6M

-5.60%

1Y

8.55%

5Y*

14.11%

10Y*

10.45%

*Annualized

Monthly Returns

The table below presents the monthly returns of ROIV, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-5.92%-3.50%-6.05%15.16%-8.43%-10.06%
2024-10.95%14.40%-7.87%3.42%-4.95%2.03%2.65%12.72%-5.64%0.09%10.04%-6.92%5.34%
20233.88%-2.53%-8.78%15.85%6.32%10.89%18.85%-3.42%0.95%-26.03%10.65%17.47%40.55%
2022-31.05%-9.50%-21.46%-25.30%20.33%-8.33%-2.21%-10.55%-9.55%59.63%4.28%49.07%-20.73%
2021-15.08%-16.50%52.04%7.81%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ROIV is 38, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ROIV is 3838
Overall Rank
The Sharpe Ratio Rank of ROIV is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of ROIV is 3434
Sortino Ratio Rank
The Omega Ratio Rank of ROIV is 3535
Omega Ratio Rank
The Calmar Ratio Rank of ROIV is 3939
Calmar Ratio Rank
The Martin Ratio Rank of ROIV is 3838
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Roivant Sciences Ltd. (ROIV) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Roivant Sciences Ltd. Sharpe ratios as of May 10, 2025 (values are recalculated daily):

  • 1-Year: -0.18
  • All Time: 0.06

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Roivant Sciences Ltd. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Roivant Sciences Ltd. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Roivant Sciences Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Roivant Sciences Ltd. was 79.22%, occurring on May 12, 2022. The portfolio has not yet recovered.

The current Roivant Sciences Ltd. drawdown is 21.30%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-79.22%Dec 21, 202199May 12, 2022
-37.33%Oct 4, 202111Oct 18, 202135Dec 7, 202146
-20.04%Dec 10, 20212Dec 13, 20214Dec 17, 20216

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Roivant Sciences Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Roivant Sciences Ltd., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 17.2% positive surprise.


-0.40-0.200.000.200.40AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.20
-0.24
Actual
Estimate

Valuation

The Valuation section provides an overview of how Roivant Sciences Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ROIV relative to other companies in the Biotechnology industry. Currently, ROIV has a P/S ratio of 66.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ROIV in comparison with other companies in the Biotechnology industry. Currently, ROIV has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items